Aldeyra Therapeutics
ALDX
77 hedge funds and large institutions have $141M invested in Aldeyra Therapeutics in 2018 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 33 increasing their positions, 20 reducing their positions, and 23 closing their positions.
407% more call options, than puts
Call options by funds: $436K | Put options by funds: $86K
65% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 20
13% less funds holding
Funds holding: 89 → 77 (-12)
20.15% less ownership
Funds ownership: 85.54% → 65.39% (-20%)
43% less capital invested
Capital invested by funds: $249M → $141M (-$107M)
48% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 23
75% less funds holding in top 10
Funds holding in top 10: 4 → 1 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$5.14M |
| 2 |
PM
Prosight Management
Dallas,
Texas
|
+$4.14M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
+$1.58M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.55M |
| 5 |
Verition Fund Management
Greenwich,
Connecticut
|
+$1.55M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
-$10.4M |
| 2 |
Millennium Management
New York
|
-$2.96M |
| 3 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$2.76M |
| 4 |
LCM
Laurion Capital Management
New York
|
-$2.76M |
| 5 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$2M |
ALDX Hedge Fund Activity: Q4 2018 in Review
77 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Aldeyra Therapeutics (ALDX) for Q4 2018, worth a combined $141M — down 43% from $249M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of ALDX and 12 opened new positions — a net loss of 11 holders — while 20 trimmed existing stakes and 33 added.
The largest buyer was BlackRock, adding an estimated $5.14M. The largest seller was Citigroup, cutting an estimated $10.4M.
- 77 institutional investors held Aldeyra Therapeutics (ALDX) as of Q4 2018, down from 89 in Q3 2018.
- Funds reported $141M of Aldeyra Therapeutics stock for Q4 2018, down 43% quarter-over-quarter.
- 12 funds opened new Aldeyra Therapeutics positions in Q4 2018 and 23 closed out, a net change of -11 holders.
- The largest Aldeyra Therapeutics buyer in Q4 2018 was BlackRock, an estimated $5.14M added.
- The largest Aldeyra Therapeutics seller in Q4 2018 was Citigroup, an estimated $10.4M sold.
Based on aggregated 13F filings for Q4 2018.